Stock AEMD AETHLON MEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages Aethlon Medical, Inc. OTC Bulletin Board

Equities

AEMD

US00808Y2081

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Decliners
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday
Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Aethlon Medical, Inc Announces Executive Changes
Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer
Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology
Aethlon Medical Board Approves 1-for-10 Reverse Stock Split
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee
Aethlon Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
Aethlon Medical Taps Namsa to Manage Planned Clinical Trial of Medical Device for Cancer
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022
Aethlon Medical Receives FDA Approval to Eliminate Dialysis Treatment as Requirement for Hemopurifier COVID-19 Study
Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AEMD Stock
  4. AEMD Stock
  5. News Aethlon Medical, Inc.
  6. Other languages